Figures (0)  Tables (9)
    • CharacteristicsNo. (%) of subjects
      using IUCD
      No. (%) of
      non-IUCD users
      Statistics
      Age21–2535 (23.3)31 (31.0)
      26–3045 (30.0)29 (29.0)
      31–3536 (27.0)13 (13.0)χ2 = 6.48
      36–4023 (15.3)15 (15.0)p = 0.16
      41–4511 (7.3)12 (12.0)
      Total150100
      OccupationBusiness37 (24.7)41 (41.0)χ2 = 20.2
      Employed51 (34.0)44 (44.0)p = 0.01
      House wife62 (41.3)15 (15.0)
      Total150100
      Parity125 (16.6)12 (12.0)
      252 (34.7)53 (53.0)χ2 = 8.2
      > 373 (48.7)35 (35.0)p = 0.01
      Total150100
      Marital statusSingle57 (38.0)73 (73.0)χ2 = 29.4
      Married93 (62.0)27 (27.0)p = 0.01

      Table 1. 

      Socio-demographic characteristics of study participants.

    • VariablesAdjusted odds
      ratio (AOR)
      95% CIp-value
      IUCD use245.5672.51–831.56< 0.001
      Age1.000.92–1.090.946
      Single and married0.620.15–2.600.512
      Employed and business0.750.23–2.480.634
      Housewife and business0.210.05–0.920.038
      Parity0.740.44–1.250.260

      Table 2. 

      Multivariable logistic regression on vulvovaginal candidiasis (VVC) and IUCD use.

    • IUD usageNo. examinedNo. (%) of subjects with VVCStatistics
      IUCD group150115 (76.6%)χ2 = 53.6
      Non-IUCD group10030 (30.0%)p < 0.001

      Table 3. 

      Occurrence of VVC among IUCD and non IUCD users.

    • Candida species No. (%) of IUCD
      users
      No. (%) of
      non-IUCD users
      Total Statistics
      Candida albicans 50 (43.5) 15 (50) 65 (44.8) χ2 = 55.8
      Candida glabrata 22 (19.1) 5 (16.7) 27 (18.6) p = 0.01*
      Candida krusei 26 (22.6) 8 (26.7) 34 (23.4)
      Candida tropicalis 17 (14.7) 2 (6.7) 19 (13.1)
      Total 115 (79.3) 30 (20.7) 145
      The symbol * means p is statistically significant.

      Table 4. 

      Distribution of Candida species among IUCD and non IUCD users.

    • Duration of use (year) No. examined No. (%) of subjects
      with VVC
      Statistics
      0–1 30 16 (53.3)
      2–3 60 45 (75.0) χ2 = 19.2
      4–5 25 23 (92.0) p = 0.004*
      > 6 35 31 (88.6)
      Total 150 115 (76.7)
      The symbol * means statistically significant.

      Table 5. 

      Relationship between duration of IUCD use and VVC infection rate.

    • Candida species No. of isolates
      tested
      No. (%) of biofilm
      positive isolates
      Statistics
      Candida albicans 50 30 (60.0) χ2 = 8.70
      Candida glabrata 22 7 (31.8) p = 0.17
      Candida krusei 26 10 (38.5)
      Candida tropicalis 17 8 (47.1)
      Total 115 55 (47.8)

      Table 6. 

      Candida biofilm formation by isolates from IUCD users.

    • Contraceptives No. of subjects No. of subjects
      with VVC (%)
      Statistics
      Oral contraceptives 70 18 (25.7) χ2 = 1.85
      Injectables 8 3 (37.5) p = 0.60
      Emergency contraceptives 10 4 (40.0)
      Norplant implant 12 5 (41.7)
      Total 100 30 (30.0)

      Table 7. 

      Distribution of VVC among non IUCD group on other methods of contraceptives.

    • Symptoms No. (%) of subjects
      Dysmenorrhoea 9 (6.0)
      Dyspareunia 11 (7.3)
      Erosion around the cervix 20 (13.3)
      Increased menstrual flow 9 (6.0)
      Decreased menstrual flow 10 (6.7)
      Genital pruritus 45 (30.0)
      Vaginal discharge 30 (20.0)
      Redness of the vulva 16 (10.7)

      Table 8. 

      Symptoms of vaginitis among subjects using IUCD.

    • Candida species No. of isolates Antifungal agents tested SDD' (%) No. (%) of isolates resistant (R)
      Candida albicans 50 Fluconazole 25 (50.0) 25 (50.0)
      Itraconazole 15 (30.0) 35 (70.0)
      Voriconazole 0 (0.0) 0 (0.0)
      Candida glabrata 22 Fluconazole 10 (45.5) 12 (54.5)
      Itraconazole 8 (36.4) 14 (63.6)
      Voriconazole 0 (0.0) 0 (0.0)
      Candida krusei 26 Fluconazole 10 (38.5) 16 (61.5)
      Itraconazole 8 (30.8) 18 (69.2)
      Voriconazole 6 (23.1) 0 (0.0)
      Candida tropicalis 17 Fluconazole 7(41.2) 10(58.8)
      Itraconazole 6 (35.3) 11 (64.7)
      Voriconazole 5 (29.4) 0 (0.0)
      KEY: R (%): Percentage of isolates that were resistant to the antifungal. SDD (%): Percentage of isolates with susceptible dose-dependence (SDD), meaning they require higher doses of the antifungal to be effective.

      Table 9. 

      Resistance profile of Candida species isolated from IUCD users with VVC in Calabar.